Abstract
Background: Alzheimer’s Disease (AD) is the most rampant neurodegenerative disorder
which has caused havoc worldwide. More than a century has passed since the first case of AD was reported,
but still, no stable treatment is known to humanity. The available medications only provide
temporary relief and are not a cure for the disease. The hunt for advanced techniques in drug development
has paved the way for drug repurposing, i.e., repositioning or reutilizing drugs as an innovative
approach.
Methodology: Several drugs which were repurposed for AD were collected by following PRISMA
2020 systemic review. Databases like PubMed, ScienceDirect, JSTOR, and SciELO were used for data
extraction. Further, the Drugbank database was used to download all the identified drugs. Later, the
Swiss Target Prediction tool was used to identify protein receptors for these drugs and the biological
pathway followed by them.
Results: Drugs like Zileuton, Salbutamol, Baricitinib, Carmustine, Paclitaxel, and Nilotinib were observed
to be involved in regulation of neurotransmitters. Similarly, Metformin, Liraglutide, UDCA,
and Bexarotene are involved in protein kinase cascades which also is one of the prime processes in
metabolic disorders like AD. Furthermore, drugs like Rosiglitazone, Pioglitazone, and Lonafarnib are
involved in interleukin-3 biosynthetic processes, which is again one of the most important processes
studied in AD treatment.
Conclusion: The study concluded that the reviewed drugs that follow similar biological and molecular
processes could be repurposed for AD if chosen judiciously with current medications and thus, drug
repurposing is a promising approach that can be utilized to find a cure for AD within a brief time and
fewer resources compared to de novo drug synthesis. Although certain loopholes still need to be
worked upon, the technique has great prospects. Furthermore, in silico methods can be utilized to justify
the findings and identify the best drug candidate.
Keywords:
Alzheimer’s disease, drug repurposing, neurotransmitter regulation, IL-3 regulation, kinase cascades, drugs
Graphical Abstract
[3]
Venkatachalam S, Jaiswal A, De A, Vijayakumar RK. Repurposing drugs for management of Alzheimer disease. Res J Pharm Technol 2019; 12(6): 3078-88.
[9]
Liu PP, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for AD. Signal Transduct Target Ther 2019; 4(1): 1-22.
[14]
Hernández MCR, Rodríguez MH, Wejebe JEM, Basurto JC. Involvement of free radicals in the development and progression of Alzheimer’s disease. Free Radicals and Diseases 2016; p. 215.
[15]
Jakhmola-Mani R, Islam A, Katare DP. Liver-brain axis in sporadic Alzheimer’s disease: Role of ten signature genes in a mouse model. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 2021; 20(9): 871-5.
[21]
Kuns B, Rosani A, Varghese D. Memantine. Treasure Island, FL: StatPearls Publishers 2021.
[26]
Gao C, Hölscher C, Liu Y, Li L. GSK3: A key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev in the Neurosci 2011; 23(1): 1-11.
[30]
Ganguli M. A reduced risk of AD in those who survive cancer. 2012; p. e1662.
[39]
Townsend DJ, Mala B, Hughes E, et al. Circular dichroism spectroscopy identifies the#-adrenoceptor agonist salbutamol as a direct inhibitor of tau filament formation in vitro. ACS Chem Neurosci 2020; 11(14): 2104-16.
[48]
Corcoran C, Jacobs TF. Metformin. Treasure Island, FL: StatPearls Publishers 2021.
[51]
Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists 2019.
[52]
Rodriguez BSQ, Correa R. Rosiglitazone. Treasure Island, FL: StatPearls Publishers 2021.
[53]
Singh G, Correa R. Pioglitazone 2019.
[54]
Achufusi TGO, Safadi AO, Mahabadi N. Ursodeoxycholic acid. Treasure Island, FL: StatPearls Publishers 2021.
[58]
Farrar MC, Jacobs TF. Paclitaxel. 2019.
[60]
Ahmad A, Zaheer M, Balis FJ. Baricitinib. Treasure Island, FL: StatPearls Publishers 2021.
[61]
Johnson DB, Merrell BJ, Bounds CG. Albuterol. 2018.
[62]
Bouchette D, Preuss CV. Zileuton. Treasure Island, FL: StatPearls Publishers 2021.
[64]
Egefjord L, Gejl M, Møller A, et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´ s disease-protocol for a controlled, randomized double-blinded trial. Brain 2012; 12: 14.
[66]
Panchal S, Parmar M. Prediction of novel therapeutic indication for rosiglitazone using its reported clinical side-effects: Drug repositioning by pharmacovigilance approach. 2017.